Matches in Nanopublications for { ?s ?p "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." ?g. }
Showing items 1 to 16 of
16
with 100 items per page.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.